Evidence map›Paper›PMID 39760806›Full record

SynthesisCurrent cardiology reports2025

Risk and Protective Factors of Poor Clinical Outcomes in Heart Failure with Improved Ejection Fraction Population: A Systematic Review and Meta-Analysis.

Wilbert Huang, Apridya Nurhafizah, Alvin Frederich, Alya Roosrahima Khairunnisa, Capella Kezia, Muhammad Irfan Fathoni, Sean Samban, Samuel Flindy

Abstract readMeta-AnalysisSystematic Review
PubMed Publisher
In one paragraph

Synthesis in Current cardiology reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Review
  4. Review
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Wilbert HuangFaculty of Medicine, University of Padjadjaran, Bandung, Indonesia. wilberthuang67@gmail.com.
Apridya NurhafizahFaculty of Medicine, University of Padjadjaran, Bandung, Indonesia.
Alvin FrederichFaculty of Medicine, University of Padjadjaran, Bandung, Indonesia.
Alya Roosrahima KhairunnisaFaculty of Medicine, University of Padjadjaran, Bandung, Indonesia.
Capella KeziaFaculty of Medicine, University of Padjadjaran, Bandung, Indonesia.
Muhammad Irfan FathoniFaculty of Medicine, University of Padjadjaran, Bandung, Indonesia.
Sean SambanFaculty of Medicine, University of Padjadjaran, Bandung, Indonesia.
Samuel FlindyFaculty of Medicine, University of Padjadjaran, Bandung, Indonesia.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

aimsHeart failure with improved ejection fraction (HFimpEF) patients could still develop adverse outcomes despite EF improvement. This study evaluates the risk and protective factors of poor clinical outcomes in HFimpEF patients.

methodsSystematic searching was done to include studies that evaluate the risks of developing poor outcomes in HFimpEF patients. HFimpEF is defined as improvement of 5-10% EF within 6-12 months or normalization of EF > 40%. Poor clinical outcome is defined as a composite of all-cause mortality, cardiovascular events, HF rehospitalization, and requirement of LVAD/ transplant. Odds ratios of outcome are pooled with random effects model. A subgroup analysis of multivariate analysis-only studies was also conducted.

results32 studies comprising 10,740 HFimpEF patients are included. Poor clinical outcomes followed up for approximately 3 years, are seen in 18.9% of HFimpEF patients. Twelve statistically significant factors that increase the risk of outcome are found. Among them, anemia (OR 7.69, CI 3.48-16.99, I

conclusionHFimpEF patients are not fully recovered and patient stratification based on risk and protective factors is recommended.

Indexed as

Heart FailureStroke VolumeHumansNatriuretic Peptide, BrainPeptide FragmentsPrognosisProtective FactorsRisk FactorsVentricular Function, LeftNatriuretic Peptide, BrainPeptide Fragmentspro-brain natriuretic peptide (1-76)Ejection fractionHeart failureImprovedPredictorsRecovered

Identifiers

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.